Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 178Lung Neoplasms 56NSCLC 11Neoplasms 10Neoplasm Metastasis 9Brain Neoplasms 8Carcinoma 7Bronchial Neoplasms 5Thoracic Neoplasms 4Colorectal Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Neoplasms by Site 3Meningeal Carcinomatosis 3Lung Diseases 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Noonan Syndrome 2Non Small Cell Lung Cancer Metastatic 2Neoplasms, Nerve Tissue 2Neoplasms by Histologic Type 2Carcinoma, Bronchogenic 2Triple Negative Breast Neoplasms 1

Interventions

sotorasib 1pembrolizumab 1osimertinib 1ensartinib 1binimetinib 1Nivolumab 1LY-2157299 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × osimertinib × Thoracic × Clear all
NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Allist Pharmaceuticals, Inc.

Phase 1/2 Completed
58 enrolled
Other solid neoplasmThoracic

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡